AIMS: To identify HbA1c trajectories after the start of insulin treatment and to identify clinically applicable predictors of the response to insulin therapy. METHODS: The study population comprised 1203 people with Type 2 diabetes included in the Hoorn Diabetes Care System (n = 9849). Inclusion criteria were: age ≥ 40 years; initiation of insulin during follow-up after failure to reach HbA1c levels ≤ 53 mmol/mol (7%) with oral glucose-lowering agents; and a follow up ≥ 2 years after initiating insulin. Latent class growth modelling was used to identify trajectories of HbA1c . Subjects considered to be 'off target' had HbA1c levels ≥ 53 mmol/mol (7.0%) during one-third or more of the follow-up time, and those considered to be 'on target' ha...
Aims: To evaluate the achievement of HbA1c targets in patients with type 2 diabetes mellitus in spec...
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
Objective: To learn the rates at which patients at UT Family Medicine–St. Francis (UTFM–SF) with typ...
Aims To identify HbA1c trajectories after the start of insulin treatment and to identify clinically ...
Aims: To identify subgroups of patients with type 2 diabetes mellitus (T2DM) following distinct traj...
Department of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sin...
AIMS: To describe global patterns of insulin treatment and to assess the impact of patient, provider...
Aims: To determine the changes in oral hypoglycaemic therapy and the time to incidence of insulin th...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
AIMS: To describe global patterns of insulin treatment and to assess the impact of patient, provider...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
Purpose of study: To evaluate the 3-year impact of initiating basal insulin on glycaemic control (H...
Aims/Introduction: We investigated the association between four insulin regimens, and increase in gl...
Aims. To evaluate long-term efficacy of CSII for treating type 2 diabetes patients. To make an att...
Aims: To evaluate the achievement of HbA1c targets in patients with type 2 diabetes mellitus in spec...
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
Objective: To learn the rates at which patients at UT Family Medicine–St. Francis (UTFM–SF) with typ...
Aims To identify HbA1c trajectories after the start of insulin treatment and to identify clinically ...
Aims: To identify subgroups of patients with type 2 diabetes mellitus (T2DM) following distinct traj...
Department of Endocrinology and Metabolism, University Hospital Maastricht, The Netherlands. bwo@sin...
AIMS: To describe global patterns of insulin treatment and to assess the impact of patient, provider...
Aims: To determine the changes in oral hypoglycaemic therapy and the time to incidence of insulin th...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
AIMS: To describe global patterns of insulin treatment and to assess the impact of patient, provider...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
Purpose of study: To evaluate the 3-year impact of initiating basal insulin on glycaemic control (H...
Aims/Introduction: We investigated the association between four insulin regimens, and increase in gl...
Aims. To evaluate long-term efficacy of CSII for treating type 2 diabetes patients. To make an att...
Aims: To evaluate the achievement of HbA1c targets in patients with type 2 diabetes mellitus in spec...
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
Objective: To learn the rates at which patients at UT Family Medicine–St. Francis (UTFM–SF) with typ...